What question did this study set out to answer?

April 1, 2026Open Access

Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir

Key Points

To determine the predictive value of gB2-specific IgG antibodies for maternal-fetal transmission after primary CMV infection treated with valacyclovir.
Analyzed gB2-specific IgG antibodies using immunoblot analysis
Evaluated maternal-fetal transmission risk among women with primary CMV infection
Used valacyclovir as the antiviral treatment.
Identified a subgroup with low residual risk of transmission due to gB2 IgG presence
Suggested that gB2 antibody status can enhance risk stratification for patient counseling
Improved clinical decision-making based on antibody status.

Abstract

In women with a primary CMV infection treated with valacyclovir, the presence of gB2-specific IgG antibodies on immunoblot analysis identifies a subgroup with a low residual risk of maternal-fetal transmission. Incorporating gB2-specific IgG antibodies status into risk stratification may improve patient counseling and clinical decision-making. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir

Key Points

Abstract

Cite This Study